Adaptive Biotechnologies Corporation (NASDAQ: ADPT) offered preliminary unaudited financial data indicating robust revenue growth for both the fourth quarter and full year of fiscal 2025. The company experienced remarkable increases in revenue compared to the prior year, although its stock price reflected marginal fluctuations in early trading.
For the period ending December 31, 2025, Adaptive Biotechnologies reported approximately $72 million in revenue during the fourth quarter. This figure marks a 51% increase relative to the fourth quarter of 2024. Extending this trend, the firm achieved around $277 million in revenue for the entirety of 2025, which represents a 55% year-over-year growth.
A significant contributor to this growth was the company’s minimal residual disease (MRD) revenue stream, which totaled approximately $62 million in the fourth quarter, growing 54% over the comparable 2024 quarter. For the full year, MRD revenue reached about $212 million, reflecting a 46% increase relative to 2024. When excluding regulatory milestone revenues tied to MRD, the full-year MRD revenue showed a year-over-year rise of 45%.
Furthermore, Adaptive Biotechnologies demonstrated strong expansion in its clonoSEQ testing volume, a key diagnostic product. The company administered roughly 30,000 tests in the fourth quarter of 2025 alone, which is a 43% increase over the prior year’s corresponding period. Across the entire 2025 fiscal year, clonoSEQ tests totaled approximately 105,600, representing a 39% increase from 2024.
Financial liquidity remained solid, with cash, cash equivalents, and marketable securities amounting to around $227 million as of December 31, 2025. This figure does not account for cash holdings maintained by Digital Biotechnologies, Inc.
Looking ahead, Adaptive Biotechnologies has indicated that it intends to release fully audited, comprehensive financial results for the fourth quarter and full fiscal year 2025 during its earnings call scheduled for February 2026.
Despite the encouraging revenue data and growth metrics, shares of Adaptive Biotechnologies exhibited minimal change during early trading hours. At the time of reporting, the stock was trading slightly lower by 0.11% at $18.24 per share based on data compiled by Benzinga Pro.
These preliminary financial disclosures underscore Adaptive Biotechnologies’ continuing revenue momentum, driven by strong demand for its MRD-related products and testing services. Observers await the detailed earnings release in February for a complete assessment of fiscal 2025 performance and future outlook.